Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery

Tetsuji Tanaka1, Saori Toujima, Tomoko Utsunomiya

  • 1Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641-0012, Japan. obgywmu@wakayama-med.ac.jp

Oncology Reports
|June 26, 2008
PubMed

Insights

Recurrent ovarian immature teratomas show decreased sensitivity to anticancer drugs compared to primary tumors. Adjuvant chemotherapy may reduce recurrence risk in these young women.

Area of Science:

  • Gynecologic Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Ovarian immature teratoma often affects young women desiring future pregnancies, with minimal surgery preferred.
  • Recurrence after surgery may necessitate chemotherapy, but differences between primary and recurrent tumor cells are poorly understood.

Purpose of the Study:

  • To establish and characterize animal models of recurrent ovarian immature teratoma.
  • To compare anticancer drug sensitivity and antigenicity between primary and recurrent tumor cells.

Main Methods:

  • Established experimental animal models using cultured ovarian immature teratoma cells transplanted into nude mice.
  • Compared drug sensitivity and smooth muscle actin (SMA) expression between primary and recurrent tumor cells using in vitro and in vivo models.

Main Results:

  • Recurrent tumor cells in nude mice exhibited significantly lower sensitivity to most anticancer drugs compared to primary tumor cells.
  • Primary teratoma cells showed high sensitivity to several chemotherapy agents, while recurrent cells showed less sensitivity, except to carboplatin and peplomycin.
  • Nude mouse tumor cells displayed a significant decrease in smooth muscle actin (SMA) expression compared to primary cells.

Conclusions:

  • Ovarian immature teratomas can recur after minimal surgery and may develop resistance to chemotherapy.
  • Recurrent tumors are less sensitive to many anticancer drugs, suggesting a role for adjuvant chemotherapy.
  • Alternative chemotherapy regimens like paclitaxel/carboplatin may be considered to balance efficacy and reproductive toxicity.

Related Concept Videos